Načítá se...
European Stakeholder Learnings Regarding Biosimilars: Part I—Improving Biosimilar Understanding and Adoption
BACKGROUND: Despite the benefits offered by biosimilars in terms of cost savings and improved patient access to biological therapies, and an established regulatory pathway in Europe, biosimilar adoption is challenged by a lack of knowledge and understanding among stakeholders such as healthcare prof...
Uloženo v:
| Vydáno v: | BioDrugs |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Springer International Publishing
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7669769/ https://ncbi.nlm.nih.gov/pubmed/33141421 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40259-020-00452-9 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|